The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Basically, these drugs, these rapamycin and other drugs, these mTOR inhibitors were known to be, I think first before even they were modulators of the immune system, they were known to be anti-proliferative drugs that people use to treat cancer. And so again, what I described in a simple way that I think about it is that it's a proliferation problem. So these cells that are making, in response to an injury, a real injury, they're making They're making scar tissue. And so
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
Well, no, no. I was just going to make the point, right? Which is we've sure talked a lot about my favorite drugs that end up in these drug-eluting stents. But why don't you take a moment to explain why a drug that inhibits mTOR would find its way onto the coating of a metal stent? I can't remember the exact name. I think it involved a guy who used to be a Columbia named Andy Marks. I think he actually figured this stuff out, but we'll have to go back and do a deep dive on that. But yeah, Basically, these drugs, these rapamycin and other drugs, these mTOR inhibitors were known to be, I think first before even they were modulators of the immune system, they were known to be anti-proliferative drugs that people use to treat cancer.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.